23-Jan-2026
Key deals this week: Clorox, Spirit Airlines, GSK, PayPal, and more
Seeking Alpha News (Sat, 24-Jan 3:15 PM ET)
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT) and Organon (OGN)
TipRanks (Wed, 21-Jan 4:10 AM ET)
Market Chameleon (Tue, 20-Jan 6:45 AM ET)
Organon gains on report of Sun Pharmaceutical interest
Seeking Alpha News (Tue, 20-Jan 9:38 AM ET)
Business Wire (Fri, 16-Jan 9:12 PM ET)
Business Wire (Thu, 8-Jan 1:30 AM ET)
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
Business Wire (Tue, 25-Nov 7:30 AM ET)
Organon Gains Strategic Edge with FDA Approval of First PERJETA Biosimilar POHERDY
Market Chameleon (Mon, 17-Nov 3:41 AM ET)
Business Wire (Mon, 17-Nov 5:30 AM ET)
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Organon & Co. Common trades on the NYSE stock market under the symbol OGN.
As of January 23, 2026, OGN stock price climbed to $9.76 with 4,201,479 million shares trading.
OGN has a beta of 0.48, meaning it tends to be less sensitive to market movements. OGN has a correlation of 0.02 to the broad based SPY ETF.
OGN has a market cap of $2.54 billion. This is considered a Mid Cap stock.
Last quarter Organon & Co. Common reported $2 billion in Revenue and $1.01 earnings per share. This beat revenue expectation by $29 million and exceeded earnings estimates by $.09.
In the last 3 years, OGN traded as high as $31.90 and as low as $6.18.
The top ETF exchange traded funds that OGN belongs to (by Net Assets): IJR, VTI, VB, FXH, VBR.
OGN has underperformed the market in the last year with a return of -38.5%, while SPY returned +14.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in OGN shares. However, OGN has outperformed the market in the last 3 month and 2 week periods, returning +8.1% and +21.2%, while SPY returned +2.9% and -0.7%, respectively. This indicates OGN has been having a stronger performance recently.
OGN support price is $9.41 and resistance is $10.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OGN shares will trade within this expected range on the day.
